BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a sell rating in a report issued on Thursday morning.
A number of other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of China Biologic Products from a hold rating to a sell rating in a report on Monday, January 29th. Deutsche Bank set a $105.00 price objective on shares of China Biologic Products and gave the company a buy rating in a research note on Friday, March 2nd. Finally, TheStreet cut shares of China Biologic Products from a b- rating to a c+ rating in a research note on Thursday, March 1st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $101.00.
Shares of China Biologic Products (CBPO) traded up $0.21 on Thursday, hitting $83.05. 68,448 shares of the stock were exchanged, compared to its average volume of 220,205. The stock has a market cap of $2,772.23, a P/E ratio of 17.88, a PEG ratio of 1.19 and a beta of 1.62. China Biologic Products has a 1-year low of $71.85 and a 1-year high of $120.46.
China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.01. The business had revenue of $90.10 million during the quarter, compared to the consensus estimate of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. The business’s revenue was up 16.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.95 EPS. sell-side analysts forecast that China Biologic Products will post 5.09 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of CBPO. Schroder Investment Management Group boosted its holdings in China Biologic Products by 86.5% in the third quarter. Schroder Investment Management Group now owns 1,016,092 shares of the biopharmaceutical company’s stock worth $92,799,000 after purchasing an additional 471,416 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of China Biologic Products by 5.5% during the fourth quarter. Bank of New York Mellon Corp now owns 804,495 shares of the biopharmaceutical company’s stock worth $63,370,000 after buying an additional 41,711 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of China Biologic Products by 62.9% during the third quarter. Artisan Partners Limited Partnership now owns 723,859 shares of the biopharmaceutical company’s stock worth $66,790,000 after buying an additional 279,420 shares during the last quarter. Comgest Global Investors S.A.S. raised its stake in shares of China Biologic Products by 78.5% in the fourth quarter. Comgest Global Investors S.A.S. now owns 635,752 shares of the biopharmaceutical company’s stock valued at $50,078,000 after purchasing an additional 279,500 shares in the last quarter. Finally, Macquarie Group Ltd. raised its stake in shares of China Biologic Products by 2.3% in the third quarter. Macquarie Group Ltd. now owns 601,087 shares of the biopharmaceutical company’s stock valued at $55,462,000 after purchasing an additional 13,500 shares in the last quarter. 56.27% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “China Biologic Products (CBPO) Upgraded to “Sell” by BidaskClub” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/03/16/china-biologic-products-cbpo-upgraded-to-sell-by-bidaskclub.html.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.